| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9f218ced6ba06e24bfaa38739487aa2d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate |
2016-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14b6d3b14ed188fef40858647a3966d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af1bdfd413ed0e284ef16acc43036a0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1087db7c6ff3ed733c07c8c20d046a9c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd677b318d5e3a1ede7c06ca5a3d9a1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7cb799d3224d87cb045c4c2cb959388 |
| publicationDate |
2021-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11033526-B2 |
| titleOfInvention |
Citalopram or escitalopram for use in the treatment of neurodegenerative diseases |
| abstract |
Citalopram or escitalopram, pharmaceutically acceptable salts or derivatives thereof for use in the treatment of neurodegenerative diseases The disclosure subject matter is related to the use of citalopram or escitalopram, pharmaceutically acceptable salts or derivatives thereof, in the treatment of neurodegenerative diseases that are positively influenced by the decrease of protein misfolding and/or aggregation, in particular by oral administration. |
| priorityDate |
2015-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |